Galaxy Digital Inc. Class A Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Galaxy Digital Inc. Class A Common Stock trades at $17.25 (market cap $3.48B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Galaxy Digital Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Galaxy Digital Inc. Class A Common Stock for 2 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| GLXY | ORKA | |
|---|---|---|
Market Cap | $3.48B | $5.08B |
Volume | 9,375,439 | 685,276 |
Sector | Financials | Health |
52-Week High | $42.86 | $113.08 |
52-Week Low | $16.84 | $26.19 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $5.93B | $4.21B |
Signals from Pluang's Aura AI — not financial advice
Galaxy Digital (GLXY) trades at $19.71, down 0.81% with bearish technical signals but strong analyst support. The company reported Q2 2026 EPS of -$0.09, beating expectations, though revenue declined to $57.4B in 2026 with a net loss of -$315M. Recent news includes a Citigroup upgrade to Buy and upcoming Q3 earnings on October 27, 2026.
Despite current losses, analyst consensus is bullish with an $38.20 price target (81.8% Buy ratings). Key risks include negative profit margins and cash flow challenges, but institutional buying and strategic partnerships provide upside potential if earnings improve.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Galaxy provides digital-asset financial services and data center infrastructure. Its digital-assets business includes trading, asset management, investment banking, staking, tokenization, and custody technology.
Read more on GLXY →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →